By IDSE News Staff
The FDA Antimicrobial Drugs Advisory Committee recently recommended approval for the investigational cytomegalovirus (CMV) treatment, maribavir (Takeda Pharmaceutical), to treat refractory CMV infection in post-transplant patients with or without genotypic resistance to ganciclovir, valganciclovir, foscarnet or cidofovir.
The product was recommended for both solid-organ transplant (SOT) and hematopoietic cell transplant (HCT) recipients.